Prelude Therapeutics Inc. (PRLD) - Q3 2025 10-Q Summary
Business Context and Reporting Period
Prelude Therapeutics Inc. is a precision oncology company focused on developing novel cancer medicines. This report covers the quarterly period ended September 30, 2025. The company is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company. As of November 10, 2025, there were approximately 62.9 million shares of voting and non-voting common stock outstanding.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $6.5 million | $3.0 million | $6.5 million | $3.0 million |
| Net Loss | $(19.7) million | $(32.3) million | $(83.0) million | $(98.4) million |
| Net Loss Per Share (Basic/Diluted) | $(0.26) | $(0.43) | $(1.09) | $(1.30) |
| Operating Expenses | $26.9 million | $37.4 million | $93.7 million | $108.9 million |
| Cash & Cash Equivalents | $47.5 million (as of Sept 30, 2025) | |||
| Marketable Securities | $7.4 million (as of Sept 30, 2025) | |||
| Total Liquidity (Cash + Securities) | $54.9 million (as of Sept 30, 2025) | |||
| Accumulated Deficit | $(666.6) million (as of Sept 30, 2025) |
Material Changes vs. Prior Period
- Revenue Increase: Revenue for Q3 2025 doubled to $6.5 million compared to $3.0 million in Q3 2024. This was driven by a $6.5 million upfront payment from an amended collaboration agreement with AbCellera Biologics.
- Expense Reduction: Total operating expenses decreased by $10.5 million (28%) in Q3 2025 compared to the prior year. Research and Development (R&D) expenses dropped $7.7 million, and General and Administrative (G&A) expenses dropped $2.7 million.
- Drivers of Cost Savings: The reduction in expenses was primarily due to lower stock-based compensation (SBC) resulting from lower stock valuations on recent grants and the tapering of vesting periods for prior grants. Additionally, R&D costs decreased due to the pause in clinical development of the SMARCA2 degrader program (PRT3789 and PRT7732).
- Liquidity Position: Marketable securities decreased significantly from $121.1 million at year-end 2024 to $7.4 million at Q3 2025, reflecting the maturity of securities to fund operations.
Guidance, Outlook, Risks, and Subsequent Events
- Going Concern Warning: Management has expressed substantial doubt about the company's ability to continue as a going concern. While existing cash and subsequent funding may extend the runway into 2027, recent changes to R&D programs create uncertainty around cash flow estimates. The company may not have sufficient funds to operate for the next 12 months without additional financing.
- Subsequent Events (Post-Sept 30, 2025):
- Incyte Agreement: In November 2025, the company entered an Exclusive Option Agreement with Incyte Corporation regarding its JAK2V617F JH2 inhibitor program. Incyte received an exclusive option to acquire the program for $100 million, with potential milestones up to $775 million and royalties. The deal included an initial $35 million cash payment and a $25 million equity investment (6.25 million non-voting shares).
- AbCellera Expansion: In October 2025, the company received an additional $6 million upfront payment from AbCellera under an expanded license agreement.
- Program Updates: The company announced a pause in the clinical development of its SMARCA2 degrader program to reallocate resources to the JAK2 and KAT6A programs. The KAT6A program remains on track for an IND filing in mid-2026.
- Risks: Key risks include the need for additional capital, uncertainties in clinical development, and the potential inability to secure financing on acceptable terms. The company relies heavily on collaborations and licensing for revenue.
Investor Verification Checklist
- Cash Runway: Verify the updated cash runway calculation incorporating the $60 million from Incyte and $6 million from AbCellera received post-period end.
- Going Concern Status: Monitor management's assessment of the "substantial doubt" regarding the ability to continue as a going concern in future filings.
- Incyte Option Exercise: Track the timeline for Incyte's decision to exercise the option to acquire the JAK2 program (within 15 months or upon IND-ready data delivery).
- R&D Reallocation: Confirm the impact of pausing the SMARCA2 program on future R&D burn rates and the progress of the KAT6A and JAK2 programs.
- Stock-Based Compensation: Review future SBC expenses, as the current reduction is partly due to lower stock prices and vesting schedules, which may normalize.